Selective CDK2 inhibitor developer advancing INX-315 for CDK4/6-resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumors.
- HQ
- RTP
- Sector
- biotech
- Stage
- series_b
- Total raised
- $47M
- Last round
- series_b
Founder profiles, enrichment notes, funding history, and investor connections are available to signed-in members.
Sign in to view full record